ID   KOC-7C
AC   CVCL_5307
SY   KOC-7c; KOC7C
DR   BTO; BTO:0004970
DR   BioSample; SAMN02800474
DR   Cosmic; 2074243
DR   Cosmic; 2482706
DR   GEO; GSM659380
DR   PRIDE; PXD000901
DR   Wikidata; Q54900277
RX   CelloPub=CLPUB00067;
RX   PubMed=9023415;
RX   PubMed=15534119;
RX   PubMed=26388441;
RX   PubMed=28196595;
RX   PubMed=30485824;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 45.9 hours (CelloPub=CLPUB00067).
CC   HLA typing: A*02:01,31:01; B*51,52 (PubMed=9023415).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9,12
ST   D21S11: 31,32
ST   D5S818: 11
ST   D7S820: 8,11,12
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,18
DI   NCIt; C40078; Ovarian clear cell adenocarcinoma
DI   ORDO; Orphanet_398971; Clear cell adenocarcinoma of the ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   46Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 18
//
RX   CelloPub=CLPUB00067;
RA   Tomioka Y.;
RT   "Establishment and characterization of three human ovarian clear cell
RT   carcinoma cell lines (KOC-4c, KOC-5c, KOC-7c).";
RL   J. Kurume Med. Assoc. 61:323-333(1998).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=15534119; DOI=10.1158/1078-0432.CCR-04-0279;
RA   Takemoto Y., Yano H., Momosaki S., Ogasawara S., Nishida N.,
RA   Kojiro S., Kamura T., Kojiro M.;
RT   "Antiproliferative effects of interferon-alphaCon1 on ovarian clear
RT   cell adenocarcinoma in vitro and in vivo.";
RL   Clin. Cancer Res. 10:7418-7426(2004).
//
RX   PubMed=26388441; DOI=10.1016/j.cell.2015.08.056;
RA   Creixell P., Schoof E.M., Simpson C.D., Longden J., Miller C.J.,
RA   Lou H.J., Perryman L., Cox T.R., Zivanovic N., Palmeri A.,
RA   Wesolowska-Andersen A., Helmer-Citterich M., Ferkinghoff-Borg J.,
RA   Itamochi H., Bodenmiller B., Erler J.T., Turk B.E., Linding R.;
RT   "Kinome-wide decoding of network-attacking mutations rewiring cancer
RT   signaling.";
RL   Cell 163:202-217(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//